Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24281979 | 1.00 | TDP1 (0.46) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL18944183 | 1.00 | TDP1 (0.46) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL12128655 | 0.89 | TDP1 (0.44) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL818819 | 0.88 | TDP1 (0.43) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL14572732 | 0.88 | KDM4E (0.35) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL818688 | 0.87 | TDP1 (0.42) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL9984711 | 0.85 | TDP1 (0.50) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL9984718 | 0.85 | TDP1 (0.50) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL112576 | 0.84 | TDP1 (0.49) | TDP1KDM4ETSHRHTTMAPK1 | |
| SCHEMBL15798092 | 0.84 | TDP1 (0.49) | TDP1KDM4ETSHRHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022061461-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2022-03-31 | — | — | WO | disclosed |
| EP-2346804-B1 | COMPOSITION COMPRISING CB RECEPTOR AGONISTS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2017-03-08 | — | — | EP | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1567513-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050011-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | CNR1, CNR2, ADRA2C | TDP1 3789/4885KDM4E 2762/4885TSHR 505/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | TDP1 756/4885KDM4E 2262/4885TSHR 2752/4885 |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | CYP3A43, PRMT8, MGMT | TDP1 1951/4885KDM4E 1026/4885TSHR 3573/4885 |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | TDP1 756/4885KDM4E 2262/4885TSHR 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.